Psilocybin
Optimi Health granted Natural Health Product Site Licence by Health Canada
VANCOUVER – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), an end-to-end drug researcher and formulator licensed by Health Canada to produce…
VANCOUVER – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (MDMA), natural GMP-grade psilocybin, along with natural health product formulations, is pleased to announce the receipt of its Natural Health Product Site Licence following an assessment by the Natural and Non-prescription Health Products Directorate.
Under section 29 of the Natural Health Products Regulations, the expanded licensing allows for the manufacturing, packaging, and labelling of Natural Health Products at the Company’s Princeton, British Columbia facility.
Further, the licence also gives Optimi the ability to encapsulate products on site.
“This expands our ability to produce our products on site for global market distribution,” said Optimi CEO, Bill Ciprick. “This licence enables the Company to further diversify and leverage the potential of its existing manufacturing, processing and packaging capabilities to streamline fulfilment and reduce costs across its supply chain to support continued growth.”
Today’s announcement affirms Optimi’s commitment to supplying large scale research and development programs through its 10,000 square foot GMP compliant manufacturing facility.
Optimi Health Corp. an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances such as 3,4-Methylenedioxymethamphetamine (MDMA), natural GMP-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.
psilocybin mdma psychedelic cse optimi health optimi health canada research-
Law & Regulation1 week ago
FDA to weigh safety, impact of MDMA therapy for PTSD at June meeting
-
Psychedelics1 week ago
Numinus Wellness Focused on Boosting Profitability and Expanding Community Support
-
Psychedelics1 week ago
MindMed Reports First Quarter 2024 Financial Results and Business Updates
-
Psychedelics1 week ago
Oprah Daily’s Comprehensive Guide to Psychedelics: A Milestone for Industry Acceptance
-
Law & Regulation1 week ago
Compass Pathways keeps plugging away with its psilocybin study trials
-
Psychedelics1 week ago
Optimi Health Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University’s Institute for Psychedelic Research
-
Psychedelics1 week ago
The Onion Pokes Fun at Psychedelics
-
Psilocybin1 week ago
Oregon authorities give Kaya Holdings license for psilocybin treatment clinic